Clinical Trial Details

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Relapsed/Refractory Multiple Myeloma

Categories (click each to see list of all clinical trials associated with that category): Myeloma/Plasma Cell Dyscrasia

Current Status: Open to accrual

Phase: I/II

Principal Investigator: Holstein, Sarah

Contact Information:
Amberley Proctor
+1 402-836-9171
amberley.proctor@unmc.edu

Eligibility: https://clinicaltrials.gov/ct2/show/NCT02343042#eligibility

Summary
This study will independently assess the efficacy and safety of six combination therapies for the treatment of patients with Relapsed/Refractory Multiple Myeloma (RR MM) and Newly Diagnosed Multiple Myeloma (NDMM). The combinations to be evaluated include: selinexor + pomalidomide + dexamethasone (SPd), selinexor + bortezomib + dexamethasone (SVd), selinexor + lenalidomide + dexamethasone (SRd), selinexor + pomalidomide + dexamethasone + bortezomib (SPVd), selinexor + daratumumab + dexamethasone (SDd), and selinexor + carfilzomib + dexamethasone (SKd). The abbreviations for combination treatments have been revised to use V (Velcade) for bortezomib, R (Revlimid) for lenalidomide, D (Darzalex) for daratumumab, and K (Kyprolis) for carfilzomib.